BioLineRx (BLRX) Consolidated Net Income (2013 - 2025)

BioLineRx's Consolidated Net Income history runs 13 years deep, the most recent figure standing at -$3.1 million for Q4 2025.

• In Q4 2025, Consolidated Net Income fell 5851.85% year-over-year to -$3.1 million; the TTM figure through Dec 2025 stood at -$6.8 million (up 16.34% YoY), while the FY2025 annual figure was -$7.5 million, up 19.91% from the prior year.
• Consolidated Net Income was -$3.1 million for Q4 2025 at BioLineRx, down from -$742000.0 in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $54000.0 in Q4 2024 to a low of -$19.5 million in Q4 2023.
• Historically, Consolidated Net Income has averaged -$5.5 million across 5 years, with a median of -$5.7 million in 2021.
• The sharpest annual moves came in 2024 and 2025: Consolidated Net Income jumped 100.28% in 2024, then slumped 5851.85% in 2025.
• A 5-year view of Consolidated Net Income shows it stood at -$6.4 million in 2021, then retreated by 10.6% to -$7.1 million in 2022, then slumped by 175.71% to -$19.5 million in 2023, then soared by 100.28% to $54000.0 in 2024, then plunged by 5851.85% to -$3.1 million in 2025.
• The last three Consolidated Net Income figures came in at -$3.1 million (Q4 2025), -$742000.0 (Q3 2025), and -$1.2 million (Q2 2025), per Business Quant data.